Please login to the form below
Taflinar
This page shows the latest Taflinar news and features for those working in and with pharma, biotech and healthcare.
BMS gets two new cancer approvals in Europe
all patents regardless of their BRAF status, potentially making it more useful than BRAF inhibitors such as Roche's Zelboraf (vemurafenib) and Novartis' Taflinar (dabrafenib).
Latest news
-
BMS bags US approval for Opdivo and Yervoy combo
inhibitors such as Roche's Zelboraf (vemurafenib) and GSK's Taflinar (dabrafenib).
-
NICE backs GSK’s Tafinlar for skin cancer
NICE said the information provided by GSK suggested that Taflinar works as well as Zelboraf, which also targets the BRAF V600 mutations.
-
NICE fast-tracks GSK's skin cancer drug Tafinlar
However, just as Roche was forced to discount Zelboraf's price before NICE recommended it, the new Taflinar guidance was only issued on the basis GSK discount its drug's list ... Taflinar was approved in Europe in August 2013, based on phase III results
-
GSK's personalised cancer drug Tafinlar set for European approval
Regulatory advisors recommend the melanoma drug be licensed
BMS bags US approval for Opdivo and Yervoy combo
NICE backs GSK’s Tafinlar for skin cancer
GSK's personalised cancer drug Tafinlar set for European approval
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Senior Account Manager
-
Competitive salary offered
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- Assessing the value of interim analyses in clinical trials
- AstraZeneca chooses Ireland for $360m manufacturing site
- FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19
- New data shows Roche's Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses
- Beyond yoga and smoothies – providing real support for employee well-being
- Driving Healthcare Decisions with Natural Language Processing
- FDA approves Eli Lilly’s Verzenio in high risk early breast cancer
- Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- Novo Nordisk settles US insulin pricing dispute for $100m
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Onyx Health appoints Dean Forbes
- Sandoz completes acquisition of GSK’s cephalosporin business
- Public is more comfortable with health data sharing if they know it is to support breakthrough treatments and vaccines
PMHub
Apex.co.uk Events and Exhibition Stands
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...
Latest intelligence
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
- Digital technologies: Pharma’s answer to achieving net zero emissions?
- ...
